Global CAR T Cell Therapy Market and Clinical Trials Insight 2022

Global CAR T Cell Therapy Market and Clinical Trials Insight 2022 report highlights the
ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per
report findings, the promise of CAR modified T cell therapy derives from its combined
immunologic benefits and include the specificity of a targeted antibody, the ability to expand
the T cell population and the potential for long term persistence to facilitate the ongoing
tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the
treatment modality across the multiple centers and in larger patients. Currently, there are 99
CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-
I/II clinical trials.

In recent years, researchers have identified the chimeric antigen receptor as a potential
target for molecular genetics to insert a new epitopes on the receptor region which allows a
degree of control of the immune system. CAR T cell therapy satisfy the need to explore new
and efficacious adoptive T cell therapy. The gene transfer technology could efficiently
introduce the genes encoding CARs into the immune effector cells. The transferring of
engineered T cells provides the specific antigen binding in a non-major histocompatibility
complex.

The promise of CAR modified T cell therapy derives from its combined immunologic benefits
and include the specificity of a targeted antibody, the ability to expand the T cell population
and the potential for long term persistence to facilitate the ongoing tumor surveillance. The
success in early phase trials, assess the feasibility of evaluating the treatment modality across
the multiple centers and in larger patients.

The first commercial application of CAR T Cell based therapy for the treatment of Mantle-
Non-Hodgkin's lymphoma is expected to be available from 2020. The anti-CD19 CAR T cell
therapy axicabtagene ciloleucel (KTE-C19) is developed by KITE Pharma in collaboration with
National Cancer Institute. Currently this therapy is in preregistration phase.

In future, the advancement of CAR T Cell therapy will be largely driven by academia and will
require the support for the expensive early phase clinical trials which promise to cover the
way for a new form of targeted, exportable immunotherapy for cancer patient. The
manufacturing of CD19 CAR T cell therapy CTL019 is in a way which will modernize the
process of using the therapy globally. The anticipation of regulatory and manufacturing issues

For Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 1

 Global CAR T Cell Therapy Market and Clinical Trials Insight 2022

before they arise and proactively addressing the concerns helps to accelerate the process of
bringing this promising therapeutic approach to more patients in future.

Global CAR T Cell Therapy Market and Clinical Trials Insight 2022 report highlights:

CAR T Cell Therapies Delivery Pipeline and Mechanism of Action

Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
Global CAR T Cell Therapies Clinical Pipeline by Company, Indication and Phase
Global CAR T Cell Therapies Clinical Pipeline: 99 Therapies
CAR T Cell Therapies in Highest Phase: Preregistration
Majority of CAR T Cell Therapies in Phase-I/II Trials: 16 Therapies
Global Market Scenario of CAR T Cell Therapy
Global CAR T Cell Therapy Market Future Prospects

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents
1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology

1.1 Overview

1.2 History & Development of CAR-T Technology

2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design

2.1 Structure of CAR T Cell

2.2 1nd Generation Chimeric Antigen Receptor

2.3 2nd & 3nd Generation CAR T Cell

3. Principle of Chimeric Antigen Receptor Design

3.1 CAR Modified T Cells: Targeting

For Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 2

 Global CAR T Cell Therapy Market and Clinical Trials Insight 2022

3.2 CAR Modified T Cell: Signaling

4. CAR T Cell Therapies Delivery Pipeline & Mechanism of Action

4.1 Process of CAR T Cell Therapy

4.2 Mechanism of Action

5. Approaches to Improve the CAR T Cell Therapy

5.1 Introduction

5.2 Targeting the Tumor Stroma with CAR T Cells

5.3 Targeting the Cytokine Networks

5.4 Combination Strategies for CAR T Cells

5.5 Targeting the Immune Checkpoints

6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment

6.1 Acute Lymphoblastic Leukemia

6.2 Multiple Myeloma

6.3 Brain Tumors

6.4 Lymphoma

6.5 Solid Tumors

7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase

7.1 Research

7.2 Preclinical

7.3 Clinical

7.4 Phase-I

7.5 Phase-I/II

7.6 Phase-II

7.7 Preregistration

8. Global Market Scenario of CAR T Cell Therapy

8.1 Overview

For Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 3

 Global CAR T Cell Therapy Market and Clinical Trials Insight 2022

8.2 Estimated Price Analysis of CAR T Cell Therapy

9. Global Market Size of CAR T Cell Therapy

9.1 Market Share of Cancer Immunotherapy by its Technology

9.2 CAR T Cell Therapy Market Value

10. Global CAR T Cell Therapy Market Dynamics

10.1 Favorable Parameters

10.2 Challenges

11. Global CAR T Cell Therapy Market Future Prospects

12. Competitive L&scape

12.1 Autolus

12.2 Bellicum

12.3 Bluebird

12.4 Celgene

12.5 Cellectis

12.6 Celyad

12.7 Eureka Therapeutics

12.8 Fortress Biotech

12.9 Immune Therapeutics

12.10 Juno Therapeutics

12.11 Kite Pharma

12.12 Novartis

12.13 Sorrento therapeutics

12.14 TILT Biotherapeutics

12.15 Ziopharm

For Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 4

 Global CAR T Cell Therapy Market and Clinical Trials Insight 2022

List of Figures

Figure 1-1: Historical Development of CAR T Cell Therapy

Figure 2-1: Structure of Chimeric Antigen Receptor
Figure 2-2: First Generation Chimeric Antigen Receptor
Figure 2-3: Second Generation Chimeric Antigen Receptor
Figure 2-4: Third Generation Chimeric Antigen Receptor
Figure 3-1: Targeting Mechanism of Chimeric Antigen Receptor T-Cell
Figure 3-2: Signalling Mechanism of Chimeric Antigen Receptor T Cell
Figure 4-1: Delivery Pipeline of CAR T Cell Therapy Process
Figure 4-2: CAR T Cell Therapy Mechanism of Action
Figure 5-1: Strategies to Improve CAR T Cell Therapy
Figure 6-1: CAR T Cell Therapy in Brain Tumors
Figure 6-2: Chimeric Antigen Receptor Therapy in Lymphoma
Figure 6-3: Target of Cancer Cell by Chimeric Antigen Receptor
Figure 7-1: Global CAR T Cell Therapy Clinical Pipeline by Phase (Number), 2017-2022
Figure 7-2: Global CAR T Cell Therapy Clinical Pipeline by Phase (%), 2017-2022
Figure 8-1: Adoptive T-Cell Therapy - Open Clinical Trials to Investigate the Efficacy & Safety
(%), 2015
Figure 8-2: Estimated Cost of T Cell Therapy & CAR T Cell Therapy Per Patient (US$)
Figure 9-1: Cancer Immunotherapy - Market Share of by Its Technology* (%)
Figure 9-2: Global Cancer Immunotherapeutic Market (US$ Billion), 2016-2022
Figure 9-3: Global - Predictive Market of CAR T Cell Therapeutics (US$ Million), 2016-2022
Figure 10-1: Favorable Market Parameters of CAR T Cell Therapy
Figure 10-2: Challenges to Market Growth of CAR T Cell Therapy
Figure 11-1: Future Potential Immuno-Oncology

Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor

Table 12-1: Clinical Pipelines of Products

For Report Sample Contact: neeraj@kuickresearch.com

For Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 5